2024 ISPE Biotechnology Conference

Overview

The 2024 ISPE Biotechnology Conference will bring together leading pharmaceutical and biopharmaceutical manufacturers, technology providers, academic scientists, and international regulators to network, share insights, and provide an outlook on the evolving landscape and future of the development and manufacturing of biotechnology products.

This conference will focus on unique challenges associated with innovative pharmaceutical products applied and transferred to the (new) biosimilar, bio better, and follow-up biotechnology products, like cell and gene therapy, Advanced Therapeutic Medicinal Products (ATMPs), and mRNA-based product development and new applications. In addition, the conference will feature presentations with a focus on enablers for process development, speed-to-market, sustainability, product technology transfer, new concepts for control strategy, and manufacturing.

Throughout this event, we will discuss and consider key areas and advancements in biotechnology:

Robotic arm

Artificial Intelligence

AI can potentially streamline various operational processes via enhanced automation. Explore the impact of automation and augmentation on innovative processes like ATMPs and gene therapy, redefining how we work.

Technical Presentation

Data Science-Assisted Tech Transfer

There is more data to analyze than ever before. A top priority for companies includes finding ways to increase automation, data accessibility, and speed. Learn how to utilize data science in biopharmaceutical tech transfer and process characterization, and how to address challenges and regulatory expectations.

Case Studies

Sustainability

Delve into innovative strategies and technologies to increase sustainability and reduce the environmental impact of the biopharmaceutical industry.

Case Studies

Quality and Regulatory

Discover the added value of digitalized Quality Management in ensuring the effectiveness and compliance of quality systems, for reduced inspection risks, and support for a more reliable drug supply chain.

Case Studies

Novel Technology Innovations

Uncover technological advancements in pharmaceutical manufacturing, including the expedited production of innovative therapies and the integration of robotics and single-use systems to meet current regulatory demands.

Case Studies

Lifecycle Strategies

Dive into strategies for accelerating commercialization and time-to-market through the product life cycle. The conference will feature approaches aimed at reducing development cycles and enhancing the introduction of processes into facilities.

Case Studies

Facility Design

Explore the challenges, trends, and driving factors behind Biopharmaceutical Facility Design, such as facility planning considerations, economic viability, and regulatory requirements from a CCS and QRM perspective.

Case Studies

Expert Insights

Expert Insights: Hear from industry leaders and regulators who will share their perspectives on the future of pharmaceuticals.


Call for Proposals Timeline

  • Submission Opens
  • Submission Deadline
  • Notifications Sent

Submit Proposal


Proposal Submission Topics

The 2024 Biotechnology Conference program committee is requesting proposals aligning with the following content areas:


Proposal Submission Type

Individual Oral Presentation

20-minute presentation, to be made part of a larger session by the Planning Committee. The presentation should focus on new and innovative trends, a specific real-world strategy or campaign, a case study/use case, or a “how-to" presentation intended to help attendees gain a better understanding of the initiative and best practices that can be applied to day-to-day objectives or overall mission.


Proposal Guidelines

  • All presentations must be free of commercial intent. Incomplete proposals will not be considered.
  • By submitting a proposal, you acknowledge that, if your proposal is accepted, the speaker will attend/present in-person at the event and the speaker’s attendance at the event will be supported by their organisation.
  • Accepted speakers are responsible for their own travel and accommodations.
  • Speakers giving at least a 20-minute presentation (not including Q&A) receive complimentary conference registration.
  • NOTE: Exhibitors who are accepted to present are required to register as a paid conference attendee (with discounted registration rate). Complimentary booth staffing registrations cannot be utilised for the presentations as these are part of the education sessions and not the exhibition.
  • Consulting firms or vendor/suppliers are expected to include a speaker from an owner company to present.
  • Regulators interested in submitting a proposal: Please contact Brandy Berry submit your abstract.

AnchorProgram Committee

Phillip R. Smith, PhD
Director, Process Technology
GlaxoSmithKline
Chair
Vivianne J. Arencibia
Vice President, Global Quality Systems and Compliance
Moderna
Board Liaison
Laura-Ann Shaa Ling Chin, BSc, MSc, PE
Director, Life Sciences
Barry-Wehmiller Design Group
Richard Denk
Senior Consultant Aseptic Processing & Containment
SKAN AG
David Doleski
Head of Global Quality Audit and External Engagement
Sanofi
Liz M. Dooley, MSc
Senior Director, Global Engineering & Technology
Johnson & Johnson
Jean Francois Duliere
Reg Advisor
ISPE
Prudence Edwards
Operational Excellence Specialist
Thermo Fisher Scientific Brisbane, Australia
Ylva Ek
Founder
Robur Life Science Advisory AB
David Estapé, PhD
Technology Manager Biotechnology
CRB Group GmbH
Placeholder Person Graphic
Meli Gallup
Genentech Inc
Christoph Herwig, PhD
Senior Scientific Advisor
Körber Pharma Austria
Laura Kuger
PhD Candidate
Karlsruhe Institute of Technology (KIT)
Emerging Leader
Antonio R. Moreira, PhD
Vice Provost, Academic Affairs
University of Maryland
Joseph Olewinski
Quality Engineer
Barry-Wehmiller Design Group
Emerging Leader
Hilal Yamaner
Process Engineer
VTU Engineering Schweiz AG
Emerging Leader
Thomas Zahel, PhD
Head of Innovation
Körber Pharma Austria GmbH